Skip to main
DERM
DERM logo

DERM Stock Forecast & Price Target

DERM Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Journey Medical Corp has demonstrated significant growth in payer access, expanding coverage from approximately 30% of commercial lives in May to about 65% by July, which translates to over 100 million lives. Additionally, the company has seen a remarkable increase in prescriber adoption, rising from around 660 in the first quarter to more than 1,800 by the second quarter, underscoring its rapid market traction. Furthermore, Journey's established brand value, particularly with products like Accutane, supports consumer retention and strengthens its ability to maintain market share in the competitive dermatological sector.

Bears say

Journey Medical Corp's stock faces a negative outlook primarily due to a significant decline in prescriptions for Accutane, which dropped to approximately 66,000 in Q1 2025 from 93,000 in the same quarter of 2024. Additionally, ongoing risks such as competitive pressures from both branded and generic treatments for rosacea, potential delays in the uptake of Emrosi, and various regulatory and clinical uncertainties contribute to the financial instability. The company may also encounter challenges regarding capital requirements if cash burn surpasses current projections, impacting overall financial health.

DERM has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Journey Medical Corp (DERM) Forecast

Analysts have given DERM a Strong Buy based on their latest research and market trends.

According to 3 analysts, DERM has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Journey Medical Corp (DERM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.